Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001213900-25-080942·Crystal Peak Investment Inc.
Schedule 13D ownership disclosure
LAKESHORE BIOPHARMA CO LTD
Ordinary Shares, par value $0.0002 per share · CUSIP: G9845F208
Event date: 2025-08-26
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Huaqin Xue
Shares: 21,021,332.00 · Class: 51.0%
- Crystal Peak Holdings Inc.
Shares: 21,021,332.00 · Class: 51.0%
- Crystal Peak Investment Inc.Reported CIK 0002078050
Shares: 21,021,332.00 · Class: 51.0%
- Dave Liguang Chenn
Shares: 462,760.00 · Class: 1.1%
- Oceanpine Investment Fund II LP
Shares: 410,560.00 · Class: 1.0%
- Oceanpine Capital Inc.
Shares: 52,200.00 · Class: 0.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-080942
- Form type
- SCHEDULE 13D/A
- Filer
- Crystal Peak Investment Inc.
- CIK
- CIK 2078050
- Filed
- Aug 27, 2025
- Reporting period
- Aug 26, 2025
- Description
- Schedule 13D beneficial ownership